Lilly To Take $1.4 Billion Charge For Zyprexa Probe
15 CommentsBy Ed Silverman // October 21st, 2008 // 8:59 am
The drugmaker is in “advanced discussions” to settle a long-standing criminal investigation into its marketing of the antipsychotic. The disclosure comes just two weeks after Lilly settled an 18-month probe with 32 states, which contended Lilly violated consumer protection laws by urging docs to prescribe Zyprexa to patients who did not need the drug (back story).
Today, Lilly says it has “incorporate an enhanced compliance program,” which includes guidelines issued by the US Department of Health and Human Service’s Office of Inspector General. “The government’s investigation…has been ongoing for five years and we now have a heightened sense of responsibility to all our stakeholders to intensify efforts to resolve these issues,” Robert Armitage, Lilly’s senior vp and general counsel, says in a statement.
The investigation by the US Attorney in Philadelphia began in 2004 and last November, Lilly received a grand jury subpoena. Meanwhile, the State Medicaid Fraud Control Units of more than 30 states coordinated its investigation with the feds into Medicaid-related claims concerning Zyprexa marketing. However, 11 other states - Louisiana, Mississippi, Montana, New Mexico, Pennsylvania, South Carolina, Utah, West Virginia, Connecticut, Arkansas and Idaho - have filed lawsuits over Zyprexa and are not participating in the coordinated probe.
Not clear what plea Lilly will make. The US Attorney’s office declined to comment, and we are awaiting comment from Lilly.
In its statement, Lilly says that, if the ongoing discussions are successfully concluded, the drugmaker expects that they would settle the Zyprexa-related federal claims, as well as similar Medicaid-related claims of states participating in the settlement. Separately, Lilly paid $15 million to settle a lawsuit last March filed by the state of Alaska (see here).
Lilly, however, continues to face a potential class-action lawsuit by third-party payors in federal court in New York (back story) and the presiding judge has urged the drugmaker to settle those cases or possibly face racketeering charges.
UPDATE: We were sent a comment from Alex Reinert, an attorney representing David Egilman, a Brown University professor and former expert witness for plaintiffs’ lawyers in the Zyprexa litigation, who was fined $100,000 for leaking Zyprexa documents to the media (back story):
“Dr. Egilman paid a heavy personal price as a result of his release of documents that revealed Eli Lilly’s criminal conduct. Eli Lilly’s guilty plea shows that, at the same time it was threatening Dr. Egilman with criminal sanctions for revealing allegedly confidential documents, it was trying to hide its own serious misconduct, criminal activity that threatened the well-being of its patients for the sake of its profits. It is doubtful that any of this would ever have come to light but for Dr. Egilman’s actions.
“Dr. Egilman’s experience is a lesson for our justice system in which secrecy has become the presumption. Unfortunately, in a case like this all of the stakeholders in the case – the attorneys on both sides and the judge – have an interest in agreeing to overbroad protective orders and protecting from open view information with substantial implications for public health. Indeed, in the end, it is often the patients, their families, and the general public that is left in the dark, to their detriment. Hopefully, we will learn from this case – if we don’t, then we had better hope that there are more individuals like Dr. Egilman out there.”
Cynic
Business as usual for Big Pharma. Ignore regulations, break the law, make big profits, pay a fine that comes from the shareholders’ pockets, admit no wrongdoing, and key execs laugh all the way to the bank. Until there are real penalties for this disgusting behavior, like top execs paying personal fines and going to jail, this will never stop.
Yesterday Pfizer, today Lilly, tomorrow ??? just add them to the long list of fine-payers - Merck, Schering-Plough, Bristol-Myers Squibb - it goes on and on. And still no executive has paid a dollar nor gone to jail. This should be considered very criminal activity. Up with greed, to hades with patients!
not
“we now have a heightened sense of responsibility to all our stakeholders to intensify efforts to resolve these issues’
That should give comfort to all of us…….
Dan A.
The Dangers of Zyprexa, And Sealed Documents
Not long ago, I got the joy and despair of viewing many documents that were initially not to be seen, by order of the Department of Justice, yet found their way on various locations on the internet- specifically, the website: http://www.furiousseasons.com. The documents are, or were, in fact, evidence against Eli Lilly entirely representing their decade of deception promoting and over-medicating others with their drug called Zyprexa, which is in a class of medications called atypical anti-psychotics that, while a new molecular entity by definition, are in fact chemically similar to the older and typical anti-psychotiics, such as Haldol, which have proven to be somewhat safer than the new class that appears to be quite damaging to those who ingest these newer atypical antipsychotics. Of the several available atypical anti-psychotics now available, Zyprexa and Clozaril, which was the first atypical anti-psychotic, are believed to be the most adverse to the consumer of these medications compared with other medications in this class of drugs.
Launched in 1996, Eli Lilly did not appear to consider any adverse effects that may occur to those who take Zyprexa, rather they appeared to anticipate the drug to be a certain blockbuster. Yet at that time it is believed that there was reason to believe that there should be caution regarding its use. With the belief that the maker of Zyprexa is and will be exonerated from any responsibility related to Zyprexa, many surmise that Eli Lilly was pleased that others were taking Zyprexa , and was confident that they would be exonerated from any responsibility from the adverse effects of the drug, if such a situation developed.
At the time Zyprexa was granted approval for marketing, the medication was indicated only for schizophrenia and mania that exists in those with bipolar disorder. Schizophrenia has been defined as a disease that causes the sufferer to deviate from true reality, along with visual and auditory hallucinations. Bipolar disorder is another mental disorder where the victim alternates from states of heightened neurokinetics to periods of what can be brutal depression for the sufferer.
Eli Lilly, known in recent years for their focus and emphasis on marketing over science or research, greatly desired and hoped that Zyprexa would be a welcome blockbuster as they speculated, which is a medication that exceeds a billion dollars a year in sales as a minimum. Likely because of this state of greed of Eli Lilly, they did not consider or evaluate any possible damage this eventual flagship drug may cause others. And Eli Lilly appeared to have the obedient and manipulated sales force presumed to be a necessity for this monetary goal to occur without interference from the members of this promotional machine.
Pharmaceutical representatives overall are attractive and young individuals with little if any medical knowledge or training, but if they are assessed to have charming personalities along with a perception of obedience, they may be selected for this vocation with them. The sales vocation is normally associated to contain members with a high affinity for money, so corruptive acts such as off label promotion or the concept of kickbacks is not typically a consideration or concern of such people, overall, as history has shown. Therefore, if Eli Lilly’s sales representatives happen to be instructed to sell Zyprexa for dementia or depression, these coerced orders will likely be followed. So if this sales force is instructed to pay specifically targeted doctors large amounts of money for doing little or no work for this money given to such doctors, it still is not a problem for the sales force, as they likely desire to maintain their obedience to their corporate God who gives them an exceptional benefits.
A few years after Eli Lilly launched Zyprexa, they appeared anxious due to their obvious disappointment regarding the initial prediction that was speculated about the growth of this drug that was not meeting their expectations, so they had meetings throughout the nation, known as ‘plan of action’ meetings, and concluded afterwards that there is great benefit from a monetary paradigm of implementing ‘seeding trials’, as they are a mechanism for generating needed, although fabricated, data void of any scientific gain of knowledge, possibly. This amazingly was done and implemented afterwards rather overtly. Even more unbelievable is that around this time, the Zyprexa sales force was instructed by Eli Lilly management to seek out clinical trial sites, along with investigators for these trials, according to the documents referenced earlier. This is significant because the pharmaceutical industry states that education is the function of such trials by seeking discovery with their products. So if the sales force is involved in this process, it becomes a marketing tactic with the seeding trials. One company employee voiced stipulation was that the investigators had to either be Eli Lilly prescribing supporters or high volume prescribers. This protocol described was written internally, along with the etiology for performing these sham clinical trials. Anything in writing can be golden, from an illegal situation such as this appears to be according to the documents that exist.
In addition to this clinical trial plan of action, Eli Lilly instructed its sales force to utilize inaccurate promotional material that Eli Lilly gave its Zyprexa reps without exception, even though this material was false and misleading, which seems to illustrate the reckless disregard for others by Eli Lilly, according to others, along with this promotional material being greatly unbalanced and suggested uses for Zyprexa that were not indicated if not unproven, which can and has been harmful to patients in the past. To further mislead and corrupt the Zyprexa sales force, they were coerced to blunt assertively what are at this time widely recognized adverse effects of this medication, such as massive weight gain, along with glucose and lipid abnormalities- all of which are dangerous physiologically to the user of this medication.
The corrosive promotion of Zyprexa by Eli Lilly continued as the dangerous company intentionally altered certain Zyprexa articles by rewriting them, followed by being reviewed internally after this art work. The purpose was to stimulate what Eli Lilly believed was clearly absent, which was much needed commercial interest related to Zyprexa.
Then it came time to essentially buy benign support groups in hopes that this would improve the growth of Zyprexa. One example is that Eli Lilly paid the American Diabetes Association for their assistance in obtaining endocrinologist consultants, which is a medical specialty that treats, among other things, diabetes. To reduce any possibility of an unexpected contingency doing this, they went ahead and hired a good sized team of diabetes educators. In 1999, Eli Lilly altered a Zyprexa report that originally illustrated the glucose problem with the medication, and did so with deliberate intent. Eventually, the American Diabetes Association became quite the critic of Eli Lilly because of their harmful behavior regarding Zyprexa.
As a side note, there seems to be clear alliances between Eli Lilly and the Bush administration that have existed and exist presently. For example, George H.W. Bush became an Eli Lilly director after leaving the CIA and lobbied to infect third world countries with Lilly medications. He also did his best to maximize tax breaks further for this industry that now employs both himself and his political affiliation. In fact, many members of this administration have some connection with Eli Lilly. It seems to be what has become to be known as a revolving door issue once again. One could speculate that the Zyprexa campaign continued for so long because of the relationships the maker of the drug had and has with other powerful people. And this situation is not unique. Don Rumsfeld was once CEO of the pharmaceutical company, G.D. Searle, which at the time was owned by Monsanto.
The next psychotic tactic Eli Lilly created was the creation of an advisory board that was paid well by this company to focus on the progressing concerns of Zyprexa and its image. This tactic did work briefly, but did not change the view of the drug by the medical community in any way, who were progressively becoming aware of the aspects of Zyprexa.
It is at this point that the medical community began to get even more vexed and angered by Eli Lilly’s deceptive and overtly destructive tactics, which included doctors who were the company’s paid speakers that were utilized in the past. This event of Eli Lilly being ostracized was because of their clear disregard for those they are obligated to serve in the medical community.
Perhaps most disturbing was the company’s intentional holding of crucial safety information related to Zyprexa even before the drug was even approved. For example, Eli Lilly’s Zyprexa representatives were instructed without doubt to neutralize the legitimate concerns doctors may have about Zyprexa, if not outright fear regarding this deadly drug they now perceived as being a clear reality. The representatives were in agreement of continuing to dodge or neutralize legitimate concerns about Zyprexa, with the promise of Eli Lilly’s management team to fill their wallets more if they maintain obedience regarding this directive that in fact caused harm in the form of such physiological disorders as metabolic syndrome associated with Zyprexa, yet the sales force still denied the association due to the insistence of their employer. Essentially, the Zyprexa sales representatives with Eli Lilly were trained, perhaps aggressively and with coercion as in the past, to disarm negative perceptions about Zyprexa, even though these perceptions continuously proved to be valid. This deeply troubled many Zyprexa representatives, as at this point they were aware of the dangers of the drug they were promoting, yet followed the directives of Ely Lilly in order to maintain employment, many surmise.
Also, and of no great surprise, off label promotion with Zyprexa and other products marketed by Eli Lilly was a norm within the organization and certainly encouraged by Eli Lilly management. Suggesting and insisting doctors to prescribe Zyprexa for depression is one example. Amazingly, these behavioral flaws by Eli Lilly did not alter their methods, even though there was a strong perception by many others who perceived this company being both aggressive and greedy, and likely criminal in the way they chose to conduct their business, such as with the marketing of Zyprexa. Eli Lilly considered such possible criminal acts as off label promotion as ‘redefining the market’. Another example of their absurdity and apathy regarding those who they were suppose to benefit with their products, so it seems.
In the year 2000, Eli Lilly greatly expanded what was called their long term care sales force to expand Zyprexa intake in the elderly population. This, as a reminder, is not only a demonstration of fracturing regulatory statutes, but also harms this population with Zyprexa- specifically pneumonia and eventual premature death result from Zyprexa intake, it has been shown and concluded by others.
About the same time this tactic was being implemented, Eli Lilly developed another strategy to neutralize the obvious weight gain associated with Zyprexa with other patient populations. Such planning by Eli Lilly related to the marketing of Zyprexa clearly shows the company was aware of the risks of this medication to those who take it after being prescribed this drug by their health care provider.
in 2002, Eli Lilly was having financial disappointments, which again did not shock many. So to stay in form, they went on a mission to develop not speakers, but consultants who were paid greatly to align with them and to not educate others, but instead were hired to pacify other doctors in hopes that their problems with Zyprexa would be solved. After the consultant era which did not alter the perception of this drug as they had hoped, Eli Lilly continued to claim that Zyprexa was indeed the best in the class of atypical antipsychotics. Such a statement appears psychotic and surreal, to say the least, considering all that is known about Zyprexa at this time. And now the market for atypicals is about 5 billion a year with the addition of other entries by other pharmaceutical companies, so there seemed to be no end as to what Eli Lilly might try next.
Also in this year, the FDA called Eli Lilly ‘a sponsor’, according to a document. I find that a bit disturbing, yet not shocked, that Eli Lilly had covert meetings with the FDA which probably led the FDA to refer to them as a sponsor. Another document states that Eli Lilly also bribed selected reporters to speak or annotate favorably about Zyprexa, and they did, with constructed press releases.
As the new millennium progressed with the passing of a few years, lawsuits became a concern for Eli Lilly regarding Zyprexa. Doing what any responsible corporate entity would most certainly do, the upper management of Eli Lilly had the audacity to blame the media for the way they handled the perception of Zyprexa.
Around this time, Eli Lilly needed and did hire a public relations firm because of their image crisis as they also created a nationwide program implemented by their marketing department upon direction entitled, “Operation: Restore Confidence” with Zyprexa. I’m not sure how a fully rational and conscious group of Eli Lilly executives could create something so ridiculous and unrealistic. Equally unrealistic is that this program, it is believed, was to they could increase Zyprexa growth by hammering home to prescribers the astronomical efficacy of the drug which, of course, does not outweigh the damage of the drug to the patient who takes it. The risks, many conclude, outweigh the benefits, so to prescribe the drug may be unreasonable, unnecessary, and harmful.
Another failure illustrated above caused Eli Lilly to hire a group called Lifeplan Marketing, and they convinced this particular organization to create a brand new market expansion initiative by having them establish with the medical community that Zyprexa should be, in fact, the appropriate standard of care for patients, so this drug should be the gold standard. Of course, the strategy was largely ineffective.
At least one former Eli Lilly employee wanted to let everyone know he did not, nor will he ever forget, his experience as a Zyprexa representative with Eli Lilly. His name is Shahram Ahari and he aligned with a group called Pharmedout after this experience he had. Pharmedout was created due to a portion of a settlement a state received from the wrongdoing by another pharmaceutical company. He spends his days now making others aware of things such as what you have read, and has aligned himself with similar organizations such as Pharmedout. I’ve spoken with Shahram, and I admire his persistence with others by making citizens aware of what occurs within companies such as Eli Lilly.
Eli Lilly appears pathologically persistent in frightening ways. Next was a national implementation plan of action which focused on training thier Zyprexa sales force to use what was called a J.C.P. study to emphasize the numerous off label benefits of Zyprexa. At the same time, Eli Lilly determined that primary care doctors should be their number one Zyprexa targets instead of Psychiatrists. With this new focus, the sales force for Zyprexa were somehow convinced to tell doctors that fatigue is really the only side effect that presents itself with Zyprexa use. I like to believe that this plan of action did not occur, as the Zyprexa sales force at this time was aware of the aspects of the drug they were promoting.
While on this off label role with Zyprexa, they expanded their long term care efforts with this drug by taking on Aricept, and Alzheimers drug, and encouraged others to switch to Zyprexa, which in no way is similar to a drug for Alzheimer’s disease. The reaction for this misbehavior included Zyprexa being removed from Medicaid authorization in 2004, according to documents.
Doctors now were concerned about prescribing Zyprexa for legal reasons. As a response, Eli Lilly approached the team leader for Zyprexa, Allan Reier, it is believed, to develop a strategy of visiting such doctors, Psychiatrists in particular, with literature they created to reassure them that malpractice concerns were not a possibility if they prescribe Zyprexa. To reassure doctors that they would not be sued if they prescribe this drug. It was also around this time that Eli Lilly kept their distance from the media as well, according to documents.
The next tactical plan from Eli Lilly was to re-implement the blunting techniques regarding Zyprexa and its well known side effects. This of course included dodging concerns by doctors that they are normally encouraged to partner with, historically. Such tactical plans of action were associated with such clever names as, ‘Viva Zyprexa’, or Zyprexa Limitless”. Maybe the next one will be ‘Zyprexa Revenue Regression’. By the way, large pharmaceutical companies usually have meetings with their sales force a few times a year to develop new ‘plans of action’, as directed by their marketing department. Such plans usually include promotional strategies and the sales force exhausting their promotional budgets as well.
Next was those at the top at Eli Lilly to use those bonafide contract research organizations (CROs) to manufacture safety, health, and outcomes database studies. A deceptive publication plan followed, according to documents. CROs are commercial research organizations that often include substandard research investigators, along with a pharmaceutical company to sponsor of these clinical trials. Eli Lilly has the ability to alter aspects of such trials for their own benefit. This was done, it is believed, along with encouraging others in the medical community to have children take Zyprexa as well to ‘manage’ them, along with taking Eli Lilly’s attention deficit drug, Strattera, at the same time. As a result, it is believed, at least a million children were taking these drugs.
As stated earlier, previously sealed and damaging documents ordered by the Department of Justice got exposed at the end of 2006, and are accessible on the internet and some websites, such as http://www.furiousseasons.com, and these documents are what this article is based upon in large part.
Perhaps these documents, and other sealed documents from other pharmaceutical companies, should be disclosed immediately for the protection of others instead of restricting the public from viewing such documents. How these Zyprexa documents got exposed that at one time were sealed is unclear to me, but I’m glad that they were, for the protection and benefit of others.
“Character is what a man is in the dark” — Dwight Moody
Dan Abshear
Author’s note: What has been written is based upon information and belief based on information provided by others.
Dave
Is it any wonder that the FDA is very cautious about granting prasugrel approval given that Eli Lilly will be marketing the drug? And the present top management of Lilly presided over the Zyprexa marketing? It seem that they can’t be trusted to stay within label. This will not be good for the public with a potentially dangerous drug like prasugrel. personally, i think that the government should conduct criminal prosecution, demand restitution from the execs as well as the company, and throw the execs in jail for their fraudulent actions. maybe if a Democrat is elected!
Anne
I wonder if Lilly is planning to start a group called “Zyprexa Dead” for the families of all those who’ve lost their children or their parents to this drug?
The most difficult part is that Lilly hid the lethal side effects prior to FDA approval, hid the lethal side effects through ongoing subterfuge, and hides the lethal side effects even today (see lengthy article in the magazine, “Indianapolis Monthly”, out for October. In this article, a high Lilly official has the nerve to say that the drug works for some - those who have plenty of support, and not for others. Nothing about profound hyperglycemia death or pancreatitis death or whatever is causing seniors with dementia to die.
I do not understand what the special magic is that prevents these evil men from criminal trials and prison - I will never understand it. I am just glad I don’t live in Indianapolis and do not have to ever meet these men. Do they toss and turn at night or do they just have dead souls?
Chris
No tossing and turning in those beds! Their souls have been signed, sealed and delivered to the devil years ago. When they decided that making money was more important that people. It is indeed a sad statement about America when these individuals are not prosecuted, fined and jailed!!!!
matt
Well, consider youself lucky . In OZ the Doctors give Zyprexa to kids then ignore side effects and call it psychosis….some kids with Epilepsey get the double whammy…Zyprexa and Valporate…Zyprexa gives them fits hence the valporate which then gives the cancer.
Australian Psychiatric practice is akin to an experiment with other peoples kids enforce
enforced by State govts and welfare lobbies.
And guess who supports the School of Psychiatry….Eli Lilly of course.
Welcome to the land down under with a third world Mental Health System with ethics to match…none.
Request
The CEOs, current and past, need to be held accountable for their actions! Letting them off with a fine and admitting no wrongdoing is wrong. make them pay personal fines and throw them in jail. Only then will we have a hope that the American public will not be lied to again.
Daniel Haszard
Eli Lilly stalling on Zyprexa claims!
My chief complaint with the Zyprexa issue is,Lilly’s credibility over their continuous propaganda on how they are going to pay out $1.2 billion in damages.
As long as they keep up this rhetoric and don’t actually pay the issue won’t go away. They need to think about ‘putting their money where their mouth is’.
—-
All it takes for evil to triumph is for good men/women to do nothing-Danny Haszard Bangor Maine http://www.zyprexa-victims.com
Dona Wheeler/Roanoke
It is a begining, and we must remain positive and viligant in our thoughts and deeds to whit that the days when a drug can just be put out there, with little thought to the end result. One “good thing” about the bad economy is that more and more kids will be on state patrolls, and the money just ain’t there like it was. And the bad taste in some’s mouth from what just went down with Lilly, could be the warning, and the example.
I took Zyprexa, gained massive amounts of weight, and lost my family, as I was not “Normal”.
Sarah
Did someone forget something ? What about the rest of the cases still pending that need to be settled ? Medicaid and Medicare didn’t get injured , the injured people should get paid first then the insurances can get paid later . A lot of us is in debt waiting for our settlements to come . It seems like everyone-else is being settled except for the injured . The attorneys are getting paid . What about my settlement ,what about other people’s settlements ? THE INJURED NEED TO BE PAID FIRST !!!!
Steven
What’s curious is that there is no mention of the adverse events report from the FDA. Some 150 patients attempted suicide. Further, some 150 completed suicide in the the first three years Zyprexa was introduced in the market:1997-2000.
One has to wonder why Zyprexa wasn’t pulled from the market then. Just how many patients have to die from this deadly, legal drug?
Salmon
Steven,
Good question but Zyprexa’s diabetes and suicide may be the least of the problems. The 7-OH metabolite appears to be a likely cause of all the phen-fen like cardiac toxicity, shortened life expectancy, spontaneous abortions and birth defects. Note that Sandy Kweder from FDA has stated that FDA’s new guidance on drugs in pregnancy and lactation has been under development since 1997 right after Zyprexa got onto the market and when the phen-fen toxicities were announced. As for advanced discussions the Washington Post just this past week ran an article on how a number of companies are trying to come to agreements with the DOJ now before Obama takes office and they could really get nailed under a new Attorney General. Racketeering might not only involve Lilly but also might include a number of FDA officials.
What’s also interesting is Bush’s recent E.O. on succession planning for a new Attorney General which would likely kick in until Obama’s pick could be confirmed.
Salmon
Justice in Michigan
Salmon - I admire your persistence. I hope we will somewhere else where the discussion can really continue.
Onward.
Salmon
Thanks Justice. Yes the discussion will continue.
If you know certain things you find there are many ‘coincidences’ with items that appear in the press or on government or corporate websights. Like why did Jenkins say in March that FDA would miss deadlines and then later it was reported that it was due to safety concerns. Why did the FDA pregnancy and lactation guidance come out in early May. Why did FDA give orphan drug status to teugeride (sp?) for PAH (phen-fen) toxicity on May 15th. Why did the post-marketing suveillence program get issued in late May around the same time Reuters reported a study on older antipsychotics caused more cardiovascular tox than atypicals. Why did Reuters have several reports at the end of May quoting Janet Woodcock that they had gotten the message on safety. Why did Von Eschenbach give an interview to the Israeli press that evening. Why did Grassley announce the probe of Biederman on June 6th Why did on June 6th FDA also come out and file a brief with the supreme court favoring preemption. Why was Grassley involved on the 16th with the hearings on Medicaid costs and pointing out if the GAO assumptions of plateauing of costs was likely erroneous it could really blow the budget long term. Why did the same day did FDA make an announcement about the cardiovascular toxicities of the old antipsychotics but include in the classic list drugs that really are atypicals. Why did FDA announce sign a new agreement between OSE and OND about post marketing monitoring on June 26th. Why did at the same time did Pres Bush issue and EO prohibiting the rehiring of anyone who revealed anything from any government computer e.g. e-mails, etc.. Why did Fred Hassan have a meltdown on the front page of the WSJ on June 30th. Why was there in early July the decision to not issue approvable letters any longer after Aug 10th but only complete response letters. Why did Schering Plough issue the report on Vytorin and Cancer on July 23rd. Why did SP release the quarterly SEC filing 24 hours after Merck late on Friday Aug 1st, which only covered through June 30th. Why is SP’s asenapine review delayed when it should have been announced sometime in July or early Aug. Why was Ellis Unger promoted to under Bob Temple on Aug 10th. Why did at the same time the head of FDA’s EEO office suddenly move to become head of the VA’s FDA’s office. Why was tetrabenazine approved on Aug 15th. Why did Lilly announce a cooperative agreement with a small company last week for developing Cialis for treating PAH.
Although I believe I have details that may provide answers and that will connect many dots we will have to wait and see what legal mechanisms are available for revealing them.
Sometimes I feel like the character in 3 Days of the Condor.
Salmon